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SUMMARY
Background
The efficacy of re-treating genotype I hepatitis C virus (HCV) patients who
failed combination therapy with interferon ⁄ pegylated interferon (PEG-IFN)
and ribavirin remains unclear.
Aims
To quantify sustained virological response (SVR) rates with different
re-treatment regimens through meta-analysis of randomized controlled
trials (RCTs).
Methods
Randomized controlled trials of genotype I HCV treatment failure patients
that compared currently available re-treatment regimens were selected. Two
investigators independently extracted data on patient population, methods
and results. The pooled relative risk of SVR for treatment regimens was
computed using a random effects model.
Results
Eighteen RCTs were included. In nonresponders to standard inter-
feron ⁄ ribavirin, re-treatment with high-dose PEG-IFN combination therapy
improved SVR compared with standard PEG-IFN combination therapy
(RR = 1.49; 95% CI: 1.09–2.04), but SVR rates did not exceed 18% in most
studies. In relapsers to standard interferon ⁄ ribavirin, re-treatment with
high-dose PEG-IFN or prolonged CIFN improved SVR (RR = 1.57; 95%
CI: 1.16–2.14) and achieved SVR rates of 43–69%.
Conclusions
In genotype I HCV treatment failure patients who received combination
therapy, re-treatment with high-dose PEG-IFN combination therapy is
superior to re-treatment with standard combination therapy, although SVR
rates are variable for nonresponders (£18%) and relapsers (43–69%).
Re-treatment may be appropriate for select patients, especially relapsers and
individuals with bridging fibrosis or compensated cirrhosis.
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INTRODUCTION
Hepatitis C virus (HCV) infection currently affects over 3
million people in the United States1, 2 and is the leading
cause of decompensated cirrhosis (e.g. ascites, hepatic
encephalopathy, bleeding oesophageal varices), hepatocel-
lular carcinoma (HCC) and liver-related mortality in the
United States3, 4. Furthermore, the morbidity and mortal-
ity associated with HCV infection are projected to increase
steadily over the next decade.2 Although sustained viral
response (SVR) rates of 54–56% have been achieved with
interferon ⁄ pegylated interferon (PEG-IFN) and RBV com-
bination therapy,5–8 individuals with genotype I HCV
achieve SVR rates of approximately 40% or less9 and these
patients account for approximately 75% of HCV patients
in the US. Therefore, a substantial proportion of treat-
ment-naı̈ve HCV patients fail to achieve SVR with combi-
nation therapy and remain at high risk for decompensated
cirrhosis, HCC and liver-related mortality.10
When HCV-infected patients achieve SVR before
developing cirrhosis, their liver-related mortality is simi-
lar to age-matched controls.11 If HCV-infected patients
with cirrhosis achieve SVR, their rates of decompensated
cirrhosis [relative risk = 0.16; 95% CI: 0.04–0.59], HCC
[relative risk = 0.21, 95% CI 0.16–0.27] and liver-related
mortality [relative risk = 0.23; 95% CI: 0.10–0.52] are sig-
nificantly lower than similar patients who fail to achieve
SVR.12 In fact, treatment failure patients with advanced
fibrosis or cirrhosis develop decompensated cirrhosis at a
rate of 2.9% ⁄ year, develop HCC at a rate of 3.2% ⁄ year,
and suffer from liver-related mortality at a rate of
approximately 2.7% ⁄ year.12 Given the morbidity and
mortality associated with treatment failure, effective and
safe re-treatment regimens are needed. Treatment failures
include nonresponders (individuals who never clear HCV
from their serum) and relapsers (individuals who tempo-
rarily clear HCV from their serum, but do not sustain
viral clearance until 24 weeks after conclusion of ther-
apy). Among nonresponders to IFN monotherapy, two
meta-analyses demonstrated that re-treatment with IFN
and RBV combination therapy was significantly better
than re-treatment with IFN alone, but SVR was only
achieved in 13–14% of patients with combination ther-
apy.13, 14 Among relapsers after prior IFN monotherapy,
combination therapy with IFN and RBV produced SVR
rates of 47–56% of patients and was superior to re-treat-
ment with IFN alone.15, 16 However, the efficacy and
safety of re-treating nonresponders or relapsers after fail-
ing combination therapy remains unclear.
Treatment of HCV-infected individuals will probably
evolve to Specifically Targeted Anti-viral Therapy for
hepatitis C (STAT-C) with the introduction of protease
inhibitors to HCV therapy.17, 18 However, these protease
inhibitors may not be widely available in the US until
2012. Therefore, selected treatment failure patients who
are at risk for developing decompensated cirrhosis, HCC
and liver-related mortality may be appropriate candidates
for re-treatment before STAT-C therapies become avail-
able. This approach is supported by the most recent
American Association for Study of Liver Disease (AASLD)
and American College of Gastroenterology (ACG) treat-
ment guidelines.19 Although multiple randomized
controlled trials (RCTs) have assessed the efficacy of high-
dose or prolonged combination therapy vs. conventional
PEG-IFN combination therapy in treatment failures, the
optimal re-treatment regimen has not been established
and SVR rates have not been quantified precisely.
No previous systematic review has quantitatively
reviewed the study design and results of published RCTs
on this topic. The objective of our meta-analysis is to
assess the efficacy and safety of high-dose or prolonged
PEG-IFN combination therapies for the re-treatment of
HCV in patients who failed prior pegylated and non-
pegylated combination therapy. These data will also
provide a comprehensive assessment of SVR rates that
can be attained with high-dose or prolonged combina-
tion therapy and these data can be used for comparison
with SVR rates achieved with STAT-C based regimens.
As genotype I accounts for the vast majority of HCV
nonresponders and relapsers in the United States, our
meta-analysis focuses on this patient population.
METHODS
Literature search
A computer-assisted search was conducted to identify
potentially relevant publications in the OVID MEDLINE
database on 1 September 2008. The search ‘1997 to Sep-
tember 2008’ was performed using the following
exploded (exp) medical subject heading (MeSH) and
textwords: exp Hepatitis C ⁄ dt [Drug Therapy] AND exp
retreatment OR recurrence OR treatment failure.mp.
[mp=title, original title, abstract, name of substance
word, subject heading word] AND random allocation or
random$.mp or RCT.mp. This was then limited to
humans, and a search filter designed to retrieve con-
trolled clinical trials, systematic reviews, meta-analyses or
RCTs was applied. A similar search was also performed
in EMBASE from 1997 to 2008. Additional electronic
searches of Digestive Diseases Week (DDW) abstracts,
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(AASLD) meeting abstracts, American College of Gastro-
enterology (ACG) meeting abstracts and European Asso-
ciation for the Study of the Liver (EASL) meeting
abstracts from 2006 to 2008 were performed with combi-
nations of the search terms ‘hepatitis C’ AND ‘retreat-
ment’ or ‘treatment failure’ or ‘recurrence’ AND
‘controlled trial’ or ‘RCT’ or ‘randomization’. A manual
search of abstracts from these years was also performed.
Manual recursive searches of references from review arti-
cles and published RCTs that met inclusion criteria were
also performed. Finally, consultation with expert hepatol-
ogists was also performed to identify any additional
abstracts or unpublished data.
Study selection criteria
Study inclusion criteria were (i) patient population-
majority of study patients were genotype I HCV patients
who failed to achieve SVR with combination therapy
(note: studies were still included if a minority of study
patients were nongenotype I); (ii) intervention: compari-
son of two-drug regimens using currently available treat-
ments; (iii) outcome: SVR rates; and (iv) trial design:
RCT. One investigator (A.S.) reviewed the titles and
abstracts of all citations identified by the literature
search. Potentially relevant studies were retrieved. Two
investigators (A.S., A.W.) then retrieved full texts of
potentially relevant studies and applied the selection cri-
teria. Agreement between investigators for selection of
studies for the meta-analysis was >95%, and disagree-
ments were resolved by consensus. Studies published
only as abstracts were included if they had sufficient
information on study design, characteristics of partici-
pants, interventions and outcomes and ⁄ or if an author of
an abstract could provide this information. Data pub-
lished in both abstract and full manuscript forms were
derived from the full manuscript.
Data extraction
Eligible articles were reviewed in a duplicate, indepen-
dent manner by two investigators (A.S., A.W.). For each
study, the investigators recorded the study design, the
inclusion and exclusion criteria, initial treatment regimen
that study patients failed, percentage of patients with cir-
rhosis, percentage of patients with genotype 1 HCV,
number of relapsers vs. nonresponders, re-treatment reg-
imens including dose and duration of study medications,
number of patients in each treatment arm, mean age of
study patients, percentage of patients achieving the pri-
mary endpoint (SVR) and the percentage of patients
who discontinued therapy because of adverse events.
Authors were contacted as necessary for any missing
information.
Data regarding nonresponders and relapsers were anal-
ysed and reported separately. If studies reported SVR rates
separately for genotype I patients, then these data were
used for meta-analysis instead of using data for the entire
patient population. Furthermore, data from trials that
evaluated patients who initially failed IFN and RBV com-
bination therapy are reported separately from trials with
patients who initially failed PEG-IFN and RBV combina-
tion therapy. The primary outcome of interest, SVR, was
defined as an undetectable serum HCV RNA level
24 weeks after discontinuation of therapy. Two indepen-
dent reviewers (A.S. and A.W.) assessed the quality of
individual RCTs based on the Jadad scoring system,20 with
discrepancies resolved by a third reviewer (P.S.).
Statistical analysis
The primary aim of our study was to determine the effi-
cacy of different re-treatment regimens for nonrespond-
ers and relapsers to prior combination therapy. The
pooled response rate for an individual treatment regimen
was calculated as the total number of responders divided
by the total number of patients who were randomized to
receive the treatment. All outcomes were analysed on an
intention-to-treat basis. The pooled relative risk of SVR
between different treatment regimens was computed
using STATA 10 (StataCorp, College Station, TX, USA).
Estimates of effect were pooled using the DerSimonian
Laird method for a random effects model.
Heterogeneity was initially evaluated graphically by
examination of forest plots and L’Abbe plots. We further
evaluated the possibility of statistical heterogeneity by the
chi-square test of heterogeneity and the inconsistency
index (I2). A chi-square P-value <0.05 or I2 values >50%
are consistent with the possibility of substantial heteroge-
neity.21, 22 Sensitivity analysis, in which one study is
removed at a time from the model, was performed to
determine if there was possible undue influence of a sin-
gle study.23 Publication bias was initially evaluated
graphically by funnel plot analysis and then statistically
using Begg’s test.24 A symmetric funnel plot would help
rule out the possibility of small studies that were not
published because of unfavourable results.
RESULTS
Literature search
The MEDLINE and EMBASE search yielded 148 articles.
All citations were downloaded into Reference Manager
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and then EndNote. After review of the titles and
abstracts of these articles, 24 studies underwent full-text
review to determine their eligibility for the meta-analysis
and 14 were excluded. The remaining 10 studies (eight
full text articles and two abstracts) were selected after
meeting all applicable inclusion criteria (Figure 1,
Table 1). Additional searches of abstracts from the
annual meetings of American Association for Study of
Liver Diseases (AASLD), American College of Gastro-
enterology (ACG), European Association for the Study of
the Liver (EASL), and Digestive Disease Week (DDW)
from 2006 to 2008 yielded 55 potentially relevant
abstracts. After review of the titles and abstracts, 49
abstracts were excluded, and the remaining six abstracts
met all inclusion criteria. Finally, recursive literature
searches identified two additional full text articles that
met all inclusion criteria, producing a total of 18 studies
for inclusion in this meta-analysis. Two notable re-treat-
ment trials were excluded: EPIC25 was not included as it
was not a RCT, and HALT-C10 was not included because
it assessed maintenance therapy with the intent of halt-
ing disease progression instead of inducing SVR. There
was excellent agreement between the two reviewers
(kappa = 1.0). Based on symmetrical funnel plots and
statistical analysis using Begg’s test (P = 0.51), no evi-
dence of publication bias was ascertained.
On quality assessment, the majority of the full manu-
scripts (7 ⁄ 11) were adequately randomized, but not dou-
ble-blinded (Table S1). The other four full manuscripts
were randomized, but did not describe the method of
randomization in detail and received Jadad scores of 2.
The seven abstracts were possibly of similar quality, but
only received Jadad scores of 1 given insufficient detail
regarding randomization and withdrawals. Although
none of the 18 trials was double-blinded, this finding
may not be as important given the objectivity of SVR,
the primary outcome of interest.
Re-treatment of nonresponders to PEG-interferon and
ribavirin therapy
Two RCTs26, 27 have assessed the efficacy of re-treatment
in nonresponders to PEG-IFN plus RBV combination
therapy (Table 1). Neither trial included relapsers. The
REPEAT study (n = 942 patients, 91% genotype 1) was a
four-arm RCT that evaluated the impact of high-dose
induction therapy with PEG-IFN alpha 2a (360 lg ⁄ week
vs. 180 lg ⁄ week for 12 weeks) as well as longer treat-
ment duration (72 weeks vs. 48 weeks).27 All four arms
also received RBV 1000–1200 mg ⁄ day. If patients did
not achieve undetectable levels of HCV RNA after
24 weeks of therapy, then discontinuation of treatment
was allowed. The DIRECT study (n = 487 patients, 95%
genotype 1) compared two different doses of Interferon
alfacon-1 (‘consensus interferon’ or CIFN) therapy: CIFN
15 lg ⁄ day plus RBV vs. CIFN 9 lg ⁄ day plus RBV.26
Both arms also received RBV 1000–1200 mg ⁄ day. In the
DIRECT trial, 80% of the patients were null responders
to their prior course of treatment, whereas it remains
148 Citations Identified by 
Medline and EMBASE
8 Full Text Articles and 
2 Abstracts Included from Search
2 Additional Full Text Articles 
and 6 Abstracts Identified by 
Recursive Literature Searches 
24 Articles underwent 
Full-Text Review
61 Articles with monotherapy failures
11 Articles not assessing SVR
43 Articles not RCT
4 Articles not Hepatitis C
2 Articles not Retreatment
3 Articles not commercially available medications
 
6 Articles with monotherapy failures
6 Articles retreated with IFN, not PEG-IFN
1 Article not RCT
1 Article with repeat data
10 Full Text Articles and 8 Abstracts
Included in Meta-Analysis
Figure 1 | Map of the literature
search and selection process.
A. G. Singal et al.
972 Aliment Pharmacol Ther 2010; 32: 969–983
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































Meta-analysis: re-treatment of HCV nonresponders
Aliment Pharmacol Ther 2010; 32: 969–983 973







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































A. G. Singal et al.
974 Aliment Pharmacol Ther 2010; 32: 969–983

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Meta-analysis: re-treatment of HCV nonresponders
Aliment Pharmacol Ther 2010; 32: 969–983 975
ª 2010 Blackwell Publishing Ltd
unknown how many patients were null responders vs.
partial responders in the REPEAT trial.
In the REPEAT study, high-dose induction therapy
had no impact on SVR rates. However, patients who
were randomized to 72 weeks of PEG-IFN and RBV
were more likely to achieve SVR than patients receiving
48 weeks of treatment [16% (74 ⁄ 473) vs. 8% (38 ⁄ 469),
P < 0.001; RR = 1.93; 95% CI: 1.33–2.79]. In multiple
logistic regression analysis, genotype 1 patients were sig-
nificantly less likely to achieve SVR than nongenotype I
patients (P < 0.01). In the DIRECT study, patients with
genotype I had SVR rates of 6.9% (32 ⁄ 464) compared
with 47.8% (11 ⁄ 23) for nongenotype I. Patients with
genotype I randomized to CIFN 15 lg ⁄ day did not dem-
onstrate significantly higher SVR rates than patients who
received CIFN 9 lg ⁄ day [7.7% (18 ⁄ 233) vs. 6.0%
(14 ⁄ 232), P = 0.47; RR = 1.28; 95% CI: 0.65–2.51].
DIRECT trial data also demonstrated that ‘partial’
responders who achieved at least a 2-log drop during ini-
tial therapy had the ‘best likelihood of responding
[achieving SVR] to re-treatment with CIFN’ combination
therapy compared with ‘null’ responders. Meta-analysis
of these two trials was not performed given the substan-
tial clinical heterogeneity between the two trials.
High-dose CIFN and prolonged duration PEG-IFN
arms were also more likely to lead to treatment discon-
tinuation because of adverse events. In the REPEAT
study, more patients receiving 72 weeks of PEG-IFN plus
RBV discontinued therapy because of adverse events
compared with patients receiving 48 weeks of therapy
[12% (55 ⁄ 473) vs. 6% (27 ⁄ 469); P = 0.001]. In the
DIRECT study, patients treated with high dose of CIFN
15 lg ⁄ day trended towards higher rates of discontinua-
tion because of adverse events compared with patients
who received CIFN 9 lg ⁄ day [14.3% (35 ⁄ 245) vs. 21.1%
(51 ⁄ 242); P = 0.09].
Re-treatment of nonresponders to standard interferon
and ribavirin therapy
Seven RCTs have assessed the efficacy of re-treatment in
nonresponders to prior standard IFN and RBV ther-
apy.28–34 Details regarding the design of these studies are
provided in Table 1. In each of the studies, over 80% of
study patients had genotype 1 HCV with the exception
of the studies by Bergmann et al.28 and Scotto et al.34
where approximately 50–65% of patients had genotype 1
disease. However, specific data on SVR rates for geno-
type 1 HCV patients were not available for most studies.
Meta-analysis of these trials suggests that SVR rates
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Re-treatment with higher doses of PEG-IFN is more
likely to produce SVR than combination therapy regi-
mens with conventional doses of PEG-IFN: RR = 1.49;
95% CI: 1.09–2.04 (Q = 1.24, P = 0.98, I2 = 0.0%)
(Figure 2). Assessment of individual trial results suggests
that SVR rates are not significantly higher in non-
responders who failed initial therapy with standard IFN
plus RBV compared with nonresponders who failed ini-
tial therapy with PEG-IFN plus RBV (Table 1). Among
the four RCTs that randomized at least 100 patients,31–34
SVR rates were only 10–17% with high-dose PEG-IFN
and RBV combination therapy.
Although most studies compared different dosing regi-
mens of PEG-IFN, the Consensus Interferon study30
compared CIFN with PEG-IFN combination therapy. No
difference was observed between patients randomized to
CIFN vs. PEG-IFN alpha 2b [22.2% (4 ⁄ 18) vs. 22.7%
(5 ⁄ 22), P = 0.97; RR = 0.98; 95% CI: 0.31–3.11]. More-
over, no significant difference was observed when Scotto
and colleagues assessed equivalent dosing regimens of
two different forms of PEG-IFN.34 In a sensitivity analy-
sis, we removed both the Consensus Interferon study
and the Scotto study from the meta-analysis, but this did
not produce a significant change in the pooled relative
risk of SVR (RR = 1.52; 95% CI: 1.09–2.14).
Discontinuation rates because of adverse events (11–
13%) were similar for the treatment arms in most trials
(Table 1). However, in the Consensus Interferon study,
discontinuation because of adverse events was signifi-
cantly higher with CIFN than PEG-IFN [33% (6 ⁄ 18) vs.
4.5% (1 ⁄ 22), P = 0.02].
Re-treatment of relapsers to combination therapy
Four RCTs32, 33, 35, 36 studied re-treatment in relapsers
after prior treatment with combination therapy (Table 1).
In meta-analysis, SVR rates were increased with higher
dose PEG-IFN combination therapy or prolonged
(72 weeks) treatment with CIFN-based combination
therapy: RR 1.57; 95% CI: 1.16–2.14 (Q = 1.19, P = 0.76,
I2 = 0.0%) (Figure 3). Several points from these studies
deserve further emphasis. First, the largest RCT36 com-
pared re-treatment with PEG-IFN combination therapy
vs. standard IFN combination therapy and demonstrated
that the PEG-IFN combination therapy was superior:
43% vs. 26%; P < 0.001; RR = 1.93; 95% CI: 1.15–3.27).
Second, another RCT32 showed a trend for higher SVR
rates with higher dose PEG-IFN alpha 2b compared with
standard dose PEG-IFN alpha 2b: 50% (15 ⁄ 30) vs. 32.0%
(8 ⁄ 25), P = 0.18; RR = 1.56; 95% CI: 0.80–3.07. Finally,
the highest SVR (69%) was achieved with a 72-week
course of CIFN plus RBV.35 Discontinuation because of
adverse events was not reported for three studies33, 35, 36
and was only reported in combination with a nonre-
sponder population in the fourth study.32
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Figure 2 | Re-treatment of genotype I hepatitis C nonresponders to standard interferon and ribavirin therapy.
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Re-treatment of nonresponders and relapsers to prior
standard interferon and ribavirin therapy with
amantadine
Seven RCTs37–44 evaluated the possible benefit of adding
amantadine to PEG-IFN and RBV during re-treatment
(Table 1). Notably, amantadine was added to both treat-
ment arms in two studies39, 42, 43 that compared different
dosing regimens of PEG-IFN. With the exception of one
study,44 at least 67% of the study patients had genotype I
disease.
Amantadine does not appear to be beneficial based
on these studies. Meta-analysis of studies that compared
amantadine plus combination therapy vs. placebo (or
no additional treatment) plus combination ther-
apy37, 38, 40, 41, 44 demonstrated that amantadine did not
improve SVR rates compared with placebo: RR = 1.07;
95% CI: 0.70–1.64 (Q = 3.15, P = 0.53, I2 = 0.0%).
Moreover, in meta-analysis of all trials using amanta-
dine, SVR rates were not improved for regimens that
included amantadine: RR = 1.24; 95% CI: 0.90–1.72
(Q = 5.58, P = 0.472, I2 = 0.0%) (Figure 4). Only one
study provided data regarding the possible benefit of
adding amantadine to PEG-IFN based combination
therapy in relapser patients.37 There was no significant
difference in SVR rates among relapsers with the addi-
tion of amantadine to combination therapy vs. relapsers
who received more standard combination therapy:
41.2% (14 ⁄ 34) vs. 42.9% (15 ⁄ 35) (P = 0.89). Discontinu-
ation because of adverse events was not described for
most of the trials, but was similar among the two treat-
ment arms when reported.38, 41, 44
DISCUSSION
Most treatment-naı̈ve genotype I HCV patients fail to
achieve SVR with combination therapy and remain at high
risk for decompensated cirrhosis, HCC and liver-related
mortality.3, 4 Given the morbidity and mortality associated
with treatment failure, effective and safe re-treatment regi-
mens are needed,12 but re-treatment of these patients with
conventional PEG-IFN combination therapy usually has a
poor outcome. Optimal re-treatment regimens for these
patients, including high-dose or prolonged re-treatment
regimens, have not been defined. Our meta-analysis is the
first to quantify the efficacy and safety of re-treating
patients who fail combination therapy with high-dose or
prolonged PEG-IFN and RBV vs. conventional PEG-IFN
combination therapy. It demonstrates that high-dose
PEG-IFN and RBV is superior to conventional PEG-IFN
combination therapy for re-treatment of nonresponders to
standard interferon and RBV treatment regimens
(RR = 1.49; 95% CI: 1.09–2.04). Furthermore, our meta-
analysis demonstrates that relapsers to initial HCV therapy
can attain SVR rates of 43–69% during re-treatment and
this may be particularly useful to relapsers who already
have bridging fibrosis or cirrhosis and are at risk for
quickly developing sequelae of cirrhosis.
Although treatment of HCV-infected individuals will
probably advance to direct-acting antiviral (DAA) agents,



















Figure 3 | Re-treatment of genotype I hepatitis C relapsers to combination therapy.
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also known as Specifically Targeted Anti-viral Therapy
for hepatitis C (STAT-C), with protease inhibitors,17, 18
these agents may not be widely available in the US until
2012 and may not be available in other countries until
years later. Therefore, treatment failure patients who are
at risk for developing decompensated cirrhosis, HCC and
liver-related mortality may be appropriate candidates for
re-treatment before DAA therapies become available,
especially if they already have bridging fibrosis or com-
pensated cirrhosis. Furthermore, the SVR data in our
study will provide a comprehensive assessment of SVR
rates that can be attained with high-dose or prolonged
PEG-IFN combination therapy and these data can be
used for comparison with SVR rates achieved with DAA
based regimens.
As 2009 AASLD ⁄ ACG guidelines suggest that deci-
sions about re-treatment should be individualized,19 cli-
nicians need to identify treatment failure patients who
are most in-need of re-treatment and those who are
most likely to benefit.45 Clearly, relapsers with bridging
fibrosis or compensated cirrhosis appear to be appropri-
ate candidates for re-treatment as long as these individu-
als have a good understanding of the potential risks and
benefits of re-treatment and express motivation to
undergo prolonged or high-dose therapy. SVR rates
between 43% and 69% are possible in these patients with
prolonged or high-dose therapy. Nonresponders fail to
achieve similar SVR rates with re-treatment, and clini-
cians may want to identify additional factors which are
associated with successful re-treatment when making
individualized decisions for patients. The EPIC trial,25 a
large prospective multi-centre open-label trial assessing
re-treatment of 2333 patients who failed combination
therapy identified other factors associated with SVR dur-
ing re-treatment, including genotype 2 ⁄ 3 disease, low
baseline fibrosis score, low baseline viral load and prior
standard IFN based treatment. EPIC did not assess the
impact of African-American race or high body mass
index (BMI), although these factors have been associated
with decreased likelihood of achieving SVR in trials of
treatment-naı̈ve patients.
Other factors may also contribute to whether or not
patients respond to re-treatment. Based on limited
data,26 null responders (did not achieve a 2log10 drop in
HCV RNA levels during the first 12 weeks of treatment
and had treatment discontinued) are less likely to achieve
SVR with re-treatment compared with partial responders
(individuals who achieved a 2log10 drop in HCV RNA
levels during the first 12 weeks of treatment). However,
the studies in our meta-analysis did not consistently
report adequate data regarding whether patients were par-
tial responders or null responders to initial combination




























Figure 4 | Re-treatment of genotype I hepatitis C nonresponders and relapsers to standard interferon and ribavirin
therapy with amantadine.
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therapy. Future re-treatment studies should continue to
report SVR rates separately for these sub-groups. Finally,
HCV patients may be nonresponders because of a lack
of compliance with the initial treatment regimen, inap-
propriate treatment holidays, or pre-mature discontinua-
tion or inappropriate RBV dose reductions. If HCV-
RNA titers had decreased appropriately with initial ther-
apy prior to this interruption, then these patients may be
particularly likely to respond to re-treatment if they
remain compliant and avoid RBV dose reductions or
treatment holidays. Although it may be difficult for
future trials to accurately identify patients who meet
these criteria, practitioners may wish to consider re-treat-
ment in these patients.
Based on the data in our meta-analysis, clinicians
should consider the following suggestions for re-treat-
ment regimens. For patients who are nonresponders to
prior PEG-IFN and RBV combination therapy, pro-
longed therapy with PEG-IFN and RBV (72 weeks PEG-
IFN alfa2a 180 lg ⁄ week + 1000–1200 mg ⁄ day RBV)
results in the highest SVR rates. Similarly, high-dose
PEG-IFN combination therapy regimens (48 weeks PEG-
IFN alfa2b 3.0 lg ⁄ kg ⁄ week + 1000–1200 mg ⁄ day RBV)
can be used to optimize the chance of SVR with re-treat-
ment of nonresponders to standard IFN and RBV
therapy. Re-treatment of relapsers to PEG-IFN and RBV
combination therapy appears to achieve the highest SVR
rates amongst the three groups, and SVR rates of 69%35
have been achieved with 72 weeks CIFN 9 lg ⁄ day +
1000–1200 mg ⁄ day RBV (Figure 5).
When re-treating these treatment failure patients,
complete viral suppression at week 12 appears to be cru-
cial.27 In REPEAT, patients with undetectable HCV RNA
at week 12 had a 35% chance of SVR with 48 weeks of
therapy and a 57% chance of SVR with 72 weeks of ther-
apy. In contrast, those with detectable HCV RNA at
week 12 had less than a 5% chance of SVR regardless of
treatment duration. This suggests that complete viral
suppression during the first 12 weeks of re-treatment
may be critical for success. Patients with unfavourable
characteristics who have a lower chance of responding to
re-treatment should probably wait for DAA therapy with
protease inhibitors especially if these patients only have
minimal fibrosis. DAA therapy with protease inhibitors
may become available in 2012, and these agents are likely
to produce higher SVR rates than can be achieved with
combination therapy.
Our study is strengthened by the lack of heterogeneity
in our sub-group analysis. This statistical analysis provides




* Non- response defined as failure to clear HCV RNA from serum during therapy. Relapse defined as patients who were able to clear HCV RNA at
end of therapy but did not have sustained viral response at 24 weeks after therapy was compleated.



















CIFN + RBV if
good treatment
candidate #
Do not treat if
poor treatment
candidate #
Figure 5 | Algorithm for re-treatment of genotype I hepatitis C nonresponders and relapsers prior to hepatitis C virus
(HCV) therapy.
A. G. Singal et al.
980 Aliment Pharmacol Ther 2010; 32: 969–983
ª 2010 Blackwell Publishing Ltd
analyses had similar study populations, treatment regi-
mens and outcomes, making it acceptable to combine data
into a single meta-analysis. However, our meta-analysis is
limited by several other factors. First, seven studies in this
meta-analysis are only published in abstract form. There-
fore, we cannot report detailed data about frequency of
adverse events, frequency of dose reductions because of
adverse events, specific data on genotype I HCV patients,
percentage of patients with advanced fibrosis or cirrhosis,
etc. for some of the included studies. The potential impact
of this on our results remains unclear. The relative lack of
safety and tolerability data is particularly problematic
because of these drug regimens can be associated with
clinically important toxicities. Nevertheless, our meta-
analysis provides a detailed summary of study design and
results on this topic. Second, some RCTs published
recently in abstract form46, 47 did not provide adequate
data to be included in this meta-analysis. Furthermore, the
majority of RCTs published in abstract form did not pro-
vide sufficient data regarding SVR rates for genotype 1
patients. In these cases, data from the entire patient popu-
lation were used, which could lead to an overestimation of
response rates. Finally, these studies are inadequate to
determine if different dosing regimens of RBV would
impact SVR.
In conclusion, our meta-analysis demonstrates that
high-dose PEG-IFN and RBV is superior to conventional
PEG-IFN combination therapy for re-treatment of non-
responders to standard interferon and RBV treatment
regimens (RR = 1.49; 95% CI: 1.09–2.04) and relapsers
can attain SVR rates of 43–69% with different regimens.
If these patients have bridging fibrosis or cirrhosis and
other favourable prognostic factors, then re-treatment
may be appropriate while awaiting the introduction of
DAA therapy.
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